Results 251 to 260 of about 4,607,044 (267)

National Variation in Implementation of Sentinel Lymph Node Biopsy for Clinically Node-Positive Patients Undergoing Neoadjuvant Therapy. [PDF]

Ann Surg Oncol
Taylor CD, Wang T, Sinco BR, Pilewskie M, Hughes TM, Dossett LA.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.

British Journal of Surgery, 2022
BACKGROUND Neoadjuvant therapy is increasingly being used before surgery for localized pancreatic cancer. Given the importance of completing multimodal therapy, the aim of this study was to characterize surgical resection rates after neoadjuvant therapy ...
Zachary J. Brown, Victor K. Heh, H. Labiner, G. Brock, A. Ejaz, M. Dillhoff, A. Tsung, T. Pawlik, J. Cloyd   +8 more
semanticscholar   +1 more source

Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.

Annals of Surgery, 2020
BACKGROUND The addition of induction chemotherapy to concomitant neoadjuvant chemoradiation in locally advanced rectal cancer could increase pathological downstaging and act on occult micrometastatic disease, leading ultimately to a better outcome.
F. Petrelli, F. Trevisan, M. Cabiddu, G. Sgroi, L. Bruschieri, E. Rausa, M. Ghidini, L. Turati   +7 more
semanticscholar   +1 more source

Breast MRI for Evaluation of Response to Neoadjuvant Therapy.

Radiographics, 2021
Neoadjuvant therapy is increasingly being used to treat early-stage triple-negative and human epidermal growth factor 2-overexpressing breast cancers, as well as locally advanced and inflammatory breast cancers. The rationales for neoadjuvant therapy are
B. Reig, Alana A. Lewin, Linda Du, L. Heacock, H. Toth, S. Heller, Yiming Gao, L. Moy   +7 more
semanticscholar   +1 more source

Neoadjuvant Therapy for Resectable Pancreatic Cancer

Annals of Surgery, 2021
Supplemental Digital Content is available in the text Objective: The aim of this study was to pool data from randomized controlled trials (RCT) limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a neoadjuvant therapy ...
D. L. Birrer, H. Golcher, R. Casadei, S. Haile, R. Fritsch, S. Hussung, T. Brunner, R. Fietkau, T. Meyer, R. Grützmann, S. Merkel, C. Ricci, C. Ingaldi, M. Di Marco, A. Guido, C. Serra, F. Minni, B. Pestalozzi, H. Petrowsky, M. DeOliveira, W. Bechstein, C. Bruns, C. Oberkofler, M. Puhan, M. Lesurtel, S. Heinrich, P. Clavien   +26 more
semanticscholar   +1 more source

Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.

Annals of Surgery, 2020
OBJECTIVE Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with pancreatic cancer (PC), but its value as a treatment biomarker is unclear.
S. Tsai, B. George, D. Wittmann, P. Ritch, A. Krepline, M. Aldakkak, C. Barnes, K. Christians, K. Dua, Michael O. Griffin, Catherine E Hagen, W. Hall, B. Erickson, Douglas B. Evans   +13 more
semanticscholar   +1 more source

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Journal of Clinical Oncology, 2020
4007 Background: PRODIGE 23 investigated the role of neoadjuvant mFOLFIRINOX before preoperative (preop) chemoradiation (CRT), with TME-surgery and adjuvant chemotherapy (CT) in resectable locally advanced rectal cancer.
T. Conroy, N. Lamfichekh, P. Etienne, E. Rio, E. François, N. Mesgouez-Nebout, V. Vendrely, X. Artignan, O. Bouché, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. Fouchardiere, B. Juzyna, E. Rullier, F. Marchal, F. Castan, C. Borg   +19 more
semanticscholar   +1 more source

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.

Journal of Clinical Oncology, 2019
PURPOSE Total neoadjuvant therapy is a new paradigm for rectal cancer treatment. Optimal scheduling of preoperative chemoradiotherapy (CRT) and chemotherapy remains to be established.
E. Fokas, M. Allgäuer, B. Polat, G. Klautke, G. Grabenbauer, R. Fietkau, T. Kuhnt, L. Staib, T. Brunner, A. Grosu, W. Schmiegel, L. Jacobasch, J. Weitz, G. Folprecht, A. Schlenska-Lange, M. Flentje, C. Germer, R. Grützmann, M. Schwarzbach, V. Paolucci, W. Bechstein, T. Friede, M. Ghadimi, R. Hofheinz, C. Rödel   +24 more
semanticscholar   +1 more source

Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

Annals of the New York Academy of Sciences, 2020
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer.
X. Leng, H. Daiko, Yongtao Han, Y. Mao
semanticscholar   +1 more source

Neoadjuvant therapy for pancreatic cancer

Nature Reviews Clinical Oncology, 2023
C. Springfeld, C. Ferrone, M. Katz, P. Philip, T. Hong, T. Hackert, M. Büchler, J. Neoptolemos   +7 more
semanticscholar   +1 more source